Schizophrenia Trial, Recruiting NCT07098169 Sponsor: University of California, San Diego Condition: Schizophrenia
Back to Schizophrenia

Schizophrenia Trial, Recruiting

NCT07098169
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to take part and are able to give informed consent, as assessed by a short capacity test called the UBACC
  • People aged 18 to 65
  • People who have been diagnosed with schizophrenia or schizoaffective disorder (based on DSM-5 criteria), confirmed through a structured interview and medical records
  • People with at least a 6th grade reading level, as measured by a standard reading test, since reading device instructions is required
  • People whose condition and medications have been stable for at least 2 months before joining — meaning no hospital stays and no major medication changes during that time
  • People who have at least one person (such as a clinician, case manager, family member, or friend) who has contact with them at least once a month and can provide information about them to the research team
  • People who have some level of difficulty with day-to-day functioning — those who are working full-time and are fully financially responsible for their household would not meet this particular criterion

Who may not be able to join:

  • People who show more than a moderate level of disorganised thinking, as measured by a specific item on a clinical rating scale called the PANSS
  • People who have had an alcohol or substance dependence problem in the past 3 months, based on a DSM-5 interview
  • People whose current level of care makes regular outpatient therapy difficult — for example, those who are currently hospitalised or dealing with a serious medical illness
  • People who are unable to see well enough or use their hands well enough to operate a smartphone

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Amy Pinkham, PhD, The University of Texas at Dallas

Phone: 858-822-4251

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 September 2025
Est. completion
1 February 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Informant-Rated Specific Level of Function (SLOF) Scale

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov